How is lanreotide different from octreotide?

Both are somatostatin analogs with similar efficacy for acromegaly and neuroendocrine tumors. The key differences are practical. Lanreotide (Somatuline Depot) is formulated as a deep subcutaneous injection that patients or caregivers can administer at home after training. Octreotide LAR requires intramuscular injection, typically at a healthcare facility. For patients on lifelong therapy, self-injection at home versus monthly clinic visits is a meaningful quality-of-life difference. Efficacy appears comparable in head-to-head studies. Some patients prefer one over the other for tolerability reasons—injection site reactions differ slightly. Insurance coverage and cost may also influence choice. Clinically, they're largely interchangeable; practically, the self-administration option makes lanreotide more convenient for many patients.

What did the CLARINET trial show?

CLARINET was a landmark study demonstrating that lanreotide slows tumor progression in patients with non-functional neuroendocrine tumors—tumors that don't secrete hormones and thus have no symptoms to control. Previously, somatostatin analogs were mainly used for symptom management; CLARINET showed they're disease-modifying. Patients receiving lanreotide had significantly longer progression-free survival (median not reached vs. 18 months with placebo). This established lanreotide as a first-line treatment option for advanced GEP-NETs regardless of functional status. The study changed practice guidelines worldwide and expanded lanreotide's role from purely symptomatic treatment to antitumor therapy. Similar data exists for octreotide (PROMID trial), confirming this is a class effect of somatostatin analogs.

How do you self-inject lanreotide?

After proper training (usually at the prescriber's office), patients or caregivers can administer lanreotide at home. The injection is deep subcutaneous—into the fatty tissue of the upper outer quadrant of the buttock. The pre-filled syringe comes ready to use. Key steps: remove from refrigerator 30 minutes before to reach room temperature (reduces injection discomfort), clean the injection site with alcohol, insert the needle fully at 90 degrees, inject slowly over about 20 seconds, then apply pressure. Rotate injection sites between left and right buttocks each month. Most patients become comfortable with self-injection after a few cycles. The ability to inject at home, on your own schedule, is the major practical advantage over octreotide LAR.

What are the side effects of lanreotide?

Similar to octreotide and the somatostatin analog class generally. Gastrointestinal effects include diarrhea (often transient), nausea, abdominal pain, and flatulence. Gallstones develop in up to 20% of long-term users due to decreased gallbladder motility—periodic monitoring is recommended. Injection site reactions (pain, nodules, induration) occur in some patients. Blood sugar can be affected: lanreotide suppresses insulin, potentially causing hyperglycemia, though it can also reduce hypoglycemia in insulinoma patients. Bradycardia and other cardiac effects are reported rarely. Hypothyroidism can occur with long-term use. Most side effects are manageable and many decrease in severity over time as the body adjusts.

Is lanreotide used for anything besides acromegaly and NETs?

Yes, there are off-label uses and emerging indications. Polycystic liver disease (often associated with polycystic kidney disease) has shown response to lanreotide—it reduces liver volume and symptoms. This is thought to relate to somatostatin receptor expression on cyst epithelium. Dumping syndrome after gastric surgery, refractory diarrhea from various causes, and certain other hormone-secreting conditions have been treated with lanreotide. The DIPAK-1 trial studied lanreotide in autosomal dominant polycystic kidney disease; results showed slowed kidney growth though clinical benefit was modest. As understanding of somatostatin receptor biology expands, new applications may emerge.

How long do patients typically stay on lanreotide?

Often indefinitely. For acromegaly, the underlying pituitary adenoma typically persists, requiring ongoing suppression of growth hormone. For neuroendocrine tumors, treatment usually continues as long as the tumor is stable or responding, without unacceptable side effects. Some patients have been on somatostatin analogs for decades. Discontinuation generally leads to return of symptoms (in functioning tumors) or potential tumor progression. The long-acting depot formulation makes this lifelong commitment more manageable—one injection monthly versus the alternative of surgery, radiation, or disease progression. Regular monitoring (labs, imaging) determines ongoing response and need for adjustment.

What's the dosing for lanreotide?

Standard starting dose for most indications is 90mg every 4 weeks via deep subcutaneous injection. Based on response (GH/IGF-1 levels for acromegaly, symptom control for NETs), the dose can be adjusted to 60mg (if well-controlled) or 120mg (if inadequate response). Some protocols extend the interval to every 6-8 weeks for well-controlled patients on 120mg. For the antiproliferative indication (slowing tumor growth), 120mg every 4 weeks is typically used based on the CLARINET trial protocol. Dose adjustments for renal or hepatic impairment generally aren't required, though monitoring is prudent. The pre-filled syringes come in 60mg, 90mg, and 120mg strengths.

Homechevron_rightPeptideschevron_rightLanreotide

Therapeutic

scheduleHalf-life: ~23-30 days (extended release depot formulation)

Lanreotide

Lanreotide (Somatuline Depot)

shopping_cart

starResearch Grade

Purchase Lanreotide

Check Availabilityarrow_forward

Lanreotide is the other major somatostatin analog in clinical use, offering similar therapeutic benefits to octreotide with practical differences that matter to patients. Like octreotide, it suppresses growth hormone, insulin, glucagon, and gut hormones by binding somatostatin receptors. The key distinction is formulation: Somatuline Depot uses a supersaturated solution technology that forms a slow-release depot after deep subcutaneous injection. This allows self-administration or injection by caregivers, avoiding the need for healthcare facility visits that octreotide LAR requires. The CLARINET trial established lanreotide's role in slowing tumor progression in non-functional neuroendocrine tumors—an important disease-modifying indication beyond symptom control. For patients facing lifelong treatment, the self-injection convenience significantly improves quality of life. Lanreotide represents how drug delivery innovations can meaningfully differentiate therapeutically similar compounds.

verifiedRecommended Supplier

Purchase Research-Grade Lanreotide

Sourced from Ascension Peptides. Verified ≥Pharmaceutical grade purity, third-party tested.Note: For laboratory research use only.

shopping_cartBuy Now

What is Lanreotide?
Research Benefits
How Lanreotide Works
Research Applications

References

What is Lanreotide?

Research Benefits

check_circle

Suppresses growth hormone in acromegaly

check_circle

Controls symptoms of neuroendocrine tumors

check_circle

Slows tumor progression (CLARINET data)

check_circle

Self-injectable depot formulation

check_circle

Once-monthly dosing convenience

check_circle

Reduces hormone secretion from NETs

check_circle

Well-established long-term safety

check_circle

Comparable efficacy to octreotide

Research Applications

science

Acromegaly treatment

Active research area with published studies

science

Gastroenteropancreatic neuroendocrine tumors

Active research area with published studies

science

Carcinoid syndrome

Active research area with published studies

science

Tumor antiproliferative effects

Active research area with published studies

science

Polycystic kidney and liver disease

Active research area with published studies

science

Dumping syndrome

Active research area with published studies

science

Quality of life optimization

Active research area with published studies

science

Long-term disease management

Active research area with published studies

Frequently Asked Questions

Scientific References

CLARINET Trial: Lanreotide in Intestinal and Pancreatic Neuroendocrine Tumors

New England Journal of Medicine (2014)

open_in_new

Lanreotide in Acromegaly: Long-Term Efficacy

European Journal of Endocrinology (2019)

open_in_new

Somatostatin Analogs for Neuroendocrine Tumors: CLARINET Long-Term Extension

The Lancet Oncology (2017)

open_in_new

Lanreotide (Somatuline Depot)

shopping_cart

starResearch Grade

Purchase Lanreotide

Check Availabilityarrow_forward

What is Lanreotide?

Research Benefits

check_circle

Suppresses growth hormone in acromegaly

check_circle

Controls symptoms of neuroendocrine tumors

check_circle

Slows tumor progression (CLARINET data)

check_circle

Self-injectable depot formulation

check_circle

Once-monthly dosing convenience

check_circle

Reduces hormone secretion from NETs

check_circle

Well-established long-term safety

check_circle

Comparable efficacy to octreotide

Research Applications

science

Acromegaly treatment

Active research area with published studies

science

Gastroenteropancreatic neuroendocrine tumors

Active research area with published studies

science

Carcinoid syndrome

Active research area with published studies

science

Tumor antiproliferative effects

Active research area with published studies

science

Polycystic kidney and liver disease

Active research area with published studies

science

Dumping syndrome

Active research area with published studies

science

Quality of life optimization

Active research area with published studies

science

Long-term disease management

Active research area with published studies

Scientific References

CLARINET Trial: Lanreotide in Intestinal and Pancreatic Neuroendocrine Tumors

New England Journal of Medicine (2014)

open_in_new

Lanreotide in Acromegaly: Long-Term Efficacy

European Journal of Endocrinology (2019)

open_in_new

Somatostatin Analogs for Neuroendocrine Tumors: CLARINET Long-Term Extension

The Lancet Oncology (2017)

open_in_new

Lanreotide

Lanreotide (Somatuline Depot)

Purchase Lanreotide

Purchase Research-Grade Lanreotide

Table of Contents

What is Lanreotide?

Research Benefits

Research Applications

Acromegaly treatment

Gastroenteropancreatic neuroendocrine tumors

Carcinoid syndrome

Tumor antiproliferative effects

Polycystic kidney and liver disease

Dumping syndrome

Quality of life optimization

Long-term disease management

Frequently Asked Questions

How is lanreotide different from octreotide?

What did the CLARINET trial show?

How do you self-inject lanreotide?

What are the side effects of lanreotide?

Is lanreotide used for anything besides acromegaly and NETs?

How long do patients typically stay on lanreotide?

What's the dosing for lanreotide?

Scientific References

CLARINET Trial: Lanreotide in Intestinal and Pancreatic Neuroendocrine Tumors

Lanreotide in Acromegaly: Long-Term Efficacy

Somatostatin Analogs for Neuroendocrine Tumors: CLARINET Long-Term Extension

Quick Reference

Related Peptides

Lanreotide

Lanreotide (Somatuline Depot)

Purchase Lanreotide

Purchase Research-Grade Lanreotide

Table of Contents

What is Lanreotide?

Research Benefits

Research Applications

Acromegaly treatment

Gastroenteropancreatic neuroendocrine tumors

Carcinoid syndrome

Tumor antiproliferative effects

Polycystic kidney and liver disease

Dumping syndrome

Quality of life optimization

Long-term disease management

Frequently Asked Questions

How is lanreotide different from octreotide?

What did the CLARINET trial show?

How do you self-inject lanreotide?

What are the side effects of lanreotide?

Is lanreotide used for anything besides acromegaly and NETs?

How long do patients typically stay on lanreotide?

What's the dosing for lanreotide?

Scientific References

CLARINET Trial: Lanreotide in Intestinal and Pancreatic Neuroendocrine Tumors

Lanreotide in Acromegaly: Long-Term Efficacy

Somatostatin Analogs for Neuroendocrine Tumors: CLARINET Long-Term Extension

Quick Reference

Related Peptides